Solid Biosciences to cut workforce, focus on DMD gene therapy
January 09, 2020 at 08:20 AM EST
Solid Biosciences Inc said on Thursday it would cut its workforce by about one third and focus on its experimental gene therapy for muscle-wasting disorder Duchenne muscular dystrophy (DMD), after a trial of the treatment was halted in November.